Navigating AI in Healthcare: Expert Insights and FDA Draft Guidance
Navigating AI risks in healthcare just got easier with the FDA’s new draft guidance and explanations from Guillaume Gigon, Innovaderm’s VP of Technology and AI. You can even comment on the FDA draft document by April 7. Watch the video here!
Next-Gen Drug Development: The AI Advantage
In this article, we explore the transformative impact of Artificial Intelligence (AI) on drug development and clinical trials. We had the opportunity to speak with three distinguished experts in the field: Guillaume Gigon, Vice President of Technology and AI at Indero; Nardin Nakhla, Co-Founder and CTO of Simmunome; and Christian Dansereau, Founder and CEO of […]
Leveraging Technology in Phase I Clinical Trials
This white paper is a must-read for anyone involved in clinical research. Whether youâre a seasoned professional or new to the field, the insights provided will enhance your understanding and approach to Phase I studies.
